Wytske van Weerden

Dr. ir. Wytske van Weerden is an Associate Professor in the Department of Urology at Erasmus MC, where she conducts cutting-edge research in prostate cancer therapeutics and resistance mechanisms. Her work bridges pharmacology, oncology, and molecular biology to improve clinical outcomes.

Her primary research interests include prostate cancer, castration-resistant prostate cancer, docetaxel resistance, androgen receptor signaling, and patient-derived models. She investigates how tumor heterogeneity and drug interactions influence treatment efficacy, with a focus on AKT and OATP pathways.

Recent publications show a strong trend in targeted combination therapies, nanoparticle drug delivery, and mechanistic studies of chemoresistance. Her work frequently appears in high-impact oncology journals, reflecting sustained contributions to translational prostate cancer research.

Scientific Awards:

• No awards listed in the provided text.

Dr. van Weerden has supervised at least 9 academic works, indicating an active role in mentoring students and junior researchers. She has contributed to over 127 research outputs, including articles and reviews, and has been involved in collaborative grants and interdisciplinary projects, such as the 2023 dataset on holistic metastasis research. She is a key contributor to efforts improving reproducibility and clinical relevance in prostate cancer modeling.

She is part of a multidisciplinary research network at Erasmus MC, collaborating with experts in pharmacology, oncology, and bioethics. Her team engages in both experimental and conceptual research, including a notable project connecting scientific and patient perspectives in metastasis research.